### Upcoming Internal and External Funding Opportunities in Cancer Research

<table>
<thead>
<tr>
<th>Deadline</th>
<th>Funding Opportunity</th>
<th>Sponsor</th>
<th>Max Amount and Period</th>
<th>RFP Snapshot Description</th>
<th>Eligibility Notes</th>
<th>Applicant Notes</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>September 24, 2021 – 4PM CST</strong></td>
<td><strong>INTERNAL: American Cancer Society, Institutional Research Awards (ACS-IRG)</strong></td>
<td>Siteman Cancer Center</td>
<td>$30,000 for 1 year</td>
<td>“This program awards up to four WUSTL junior faculty members $30,000 for a one-year cancer research project.”</td>
<td>PI must be an Instructor or Assistant Professor at WUSTL at the time of award and be within six years of their first independent research position or faculty appointment. Individuals who have previously received this award or who already have independent, national competitive research funding from the NIH*, ACS, NSF, or VA are not eligible.</td>
<td>Only WUSTL faculty are eligible for these awards. Applicants who are not SCC members must also apply for membership at the time of submission. Awards will be contingent upon acceptance of the applicant as a member.</td>
</tr>
<tr>
<td><strong>September 27, 2021 – 5PM CST</strong></td>
<td><strong>INTERNAL: WU-ISC3 Implementation Science Pilot Grants</strong></td>
<td>WU Implementation Science for Cancer Control (WU-ISC3)</td>
<td>$75,000 for 1 year OR $120,000 over 2 years</td>
<td>These awards support the planning of a new clinical, community, or policy implementation science research project related to cancer control. Pilot grants are typically used to fund developmental or early stage work and should describe a concrete plan for further steps beyond the pilot grant (e.g., how the pilot work will lead to an R01 award). PIIs should address cancer prevention control related topics; preference will be given to topics identified from our community partners (see Attachment A). We highly encourage proposals to include community-based personnel as active members of the research team beyond a typical advisory role.</td>
<td>PIs must be faculty members at WUSTL. CO-Is may be from other institutions or non-faculty level individuals. Investigators from underrepresented groups are highly encouraged to apply. Early Start Date: March 1, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>September 27, 2021 – 5PM CST</strong></td>
<td><strong>INTERNAL: WU-ISC3 Implementation Science Methods Grants</strong></td>
<td>WU Implementation Science for Cancer Control (WU-ISC3)</td>
<td>$60,000 for 1 year OR $100,000 over 2 years</td>
<td>Methods studies may involve a range of topics including: developing and adapting measures, applying mixed-methods, developing new methods for engaging community stakeholders, and applying innovative study designs or analytic technologies in D&amp;I science. Methods studies may be informed by gaps identified by the WU-ISC3 Methods Unit and community partners.</td>
<td>PIs must be faculty members at WUSTL. CO-Is may be from other institutions or non-faculty level individuals. Investigators from underrepresented groups are highly encouraged to apply. Early Start Date: March 1, 2022</td>
<td></td>
</tr>
<tr>
<td><strong>October 1, 2021 – 5PM CST</strong></td>
<td><strong>NEW: Acquired Resistance to Therapy Network (ARTNet; U54 Clinical Trial Not Allowed)</strong></td>
<td>NIH/NCI</td>
<td>$4.25M directs over 5 years</td>
<td>The overarching goal of the ARTNet is to bridge basic, pre-clinical, and translational research along the tumor-tumor microenvironment continuum to inform new strategies that can better transition to overcome significant challenges in acquired resistance to cancer therapies. The Coordinating Center will assemble the appropriate infrastructure to facilitate and implement the administrative, outreach, collaborative and data management activities of the ARTNet.</td>
<td>Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support. Multiple principal investigator (PI) applications are strongly encouraged. Early Start Date: September 2022 Companion Funding Opportunity with ARTNet U24</td>
<td></td>
</tr>
</tbody>
</table>
LETTER OF INTENT
October 1, 2021 - 5PM CST
NIH/NCI
Award Budget: Up to $1M directs
Award Project Period: Up to 5 Years

The aim is to establish Research Centers to integrate basic and translational cancer research studies to better examine the direct causal relationships and interactions of early lesions, their environment, and host-systems as “co-organizers” of tumor initiation (or suppression) and malignant progression in conjunction with the clinical characteristics of the lesions. The ultimate goals of the TBEL program are to further understand the biological and pathophysiological mechanisms driving or restraining pre-cancers and early cancers and provide biology-backed precision prevention approaches.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Earliest Start Date: July 2022
Companion Funding Opportunity with TBEL U24.

October 6, 2021
Research Validation of High-Quality Markers for Lung Cancer: U24 (2021 Cycle and Not Allocated)
NIH/NCI/NCI/NIH
$1,050,000 over 5 years

This funding opportunity "invites applications to support the validation of molecular/biological/molecular markers (referred to as "markers" or "biomarkers") and assays for cancer detection, diagnosis, prognosis, monitoring, and prediction of response or resistance to treatment, as well as markers for cancer prevention and control. This FOA will support investigator-initiated research for both analytical and clinical validation of assays to be used in cancer treatment, control, or prevention trials supported by the NCI."

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Earliest Start Date: June 2022

October 19, 2021
Research Centers for Cancer Systems Biology: U54s (2021 Cycle and Not Allocated)
NIH/NCI
$7.5M over 5 years

The purpose of this Funding Opportunity Announcement (FOA) is to solicit multi-project U54 Research Centers to address challenges in basic cancer biology that require a coordinated systems biology approach. These Research Centers will join the existing NCI-supported Cancer Systems Biology Consortium (CSBC). The goals of the CSBC are to (1) advance understanding of mechanisms that underlie fundamental processes in cancer; (2) support the broad application of systems biology approaches in cancer research; and (2) support the growth of a strong, stable, and diverse research community in cancer systems biology.

Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with his/her organization to develop an application for support. Individuals from underrepresented racial and ethnic groups as well as individuals with disabilities are always encouraged to apply for NIH support.

Earliest Start Date: July 2023

October 1, 2021
Research Scholar Grant
American Cancer Society
$135,000 over 3 to 5 years

"The CSBG provides support for protected time to allow junior faculty who are patients to be mentored and participate in research training to aid their development as independent clinical scientists."

Eligible applicants are licensed clinicians who are US citizens within the first 5 years of their initial faculty appointment and have an active role in patient care.

Special Initiative-Property Focus: Health Equity Research in Cancer Control and Prevention
Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at Floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.

October 16, 2021
Research Scholar Grant
American Cancer Society
$600,000 over 4 years

"The Research Scholar Grant (RSG) supports investigator initiated projects across the cancer research continuum."

Eligible applicants include independent investigators in the first 8 years of an independent research career or faculty appointment. Eligibility is extended for 30 years for clinician scientists who remain active in clinical care. Applicants typically must be within 14 years of receiving a terminal (doctorate) degree and cannot have more than one RSG/R15-like grant (>150,000/year direct costs for more than 3 years) as principal investigator at the time of application.

Special Initiative-Property Focus: Health Equity Research in Cancer Control and Prevention
Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at Floydg@wustl.edu with any questions and for assistance with reviewing/editing your proposal.
<table>
<thead>
<tr>
<th>Date</th>
<th>RFA: Role of Health Policy and Health Insurance in Approaching to Early Detection and Treatment Services</th>
<th>American Cancer Society</th>
<th>$1M over 5 years</th>
<th>“A call for research that evaluates the impact of the many changes now occurring in the healthcare system with a particular focus on cancer prevention, control, and treatment. Research to be funded by this RFA should focus on the changes in national, state, and local policy and the response to these changes by healthcare systems, insurers, patients, communities, practices, and others.”</th>
<th>Eligible applicants include independent investigators at all stages of their career.</th>
<th>This RFA will utilize the Research Scholar Grant (RSG) mechanism. Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a> with any questions and for assistance with reviewing/editing your proposal.</th>
</tr>
</thead>
<tbody>
<tr>
<td>October 15, 2021</td>
<td>Division of Cancer Biology - Multi-Consortia Coordinating Center (U24) Clinical Trial Not Allowed</td>
<td>NIH/NCI</td>
<td>$1.2M over 5 years</td>
<td>This FOA aims to create a common coordinating body to facilitate collaborations, resource sharing, and outreach activities across DCB programs. SCBR research programs to be coordinated by the DCB-MC Consorction Coordinating Center (MCZ Center) include the Cancer Genome Biology Imaging Research Resource (CGBRIR), the Cancer Systems Biology Consortium (CSBC), the Cancer Tissue Engineering Collaborative (CTEC), the Metastasis Research Network (MrNet), the Patient-Derived Models of Cancer Initiative (PDMC), and the Physical Sciences-Derived Models of Cancer Initiative (PSTMCI). In carrying out its role, the MCZ Center is expected to work collaboratively with DCB research program investigators, other investigators collaborating with SCBR research programs, and MC2 program staff.</td>
<td>Applicants for the MCZ Center need to have sufficiently broad scientific expertise in the field of cancer research, including relevant aspects of bioinformatics and computational biology, that would allow them to play a leadership role in fulfilling the scientific objectives of the various SCBR research programs assigned for coordination.</td>
<td>Earliest Start Date: July 2022</td>
</tr>
<tr>
<td>October 15, 2021</td>
<td>AACR-AstraZeneca Career Development Award for Physician Scientists (in honor of Jose Baselga)</td>
<td>AACR/AstraZeneca</td>
<td>$100,000 over 3 years</td>
<td>This award has been established to honor the life and legacy of Dr. Jose Baselga, who was a scientific leader and supportive mentor to an entire generation of physician-scientists. This program aims to encourage and support junior physician-scientists to conduct research that fosters the development of innovative targeted therapeutics. The proposed projects may be translational or clinical in nature and focused on all aspects of oncology.</td>
<td>Applicants must be at or below the level of Assistant Professor and able to commit at least 50% of full-time effort to research. Applicants must be active AACR members or must submit an application for membership by the LOI deadline. Must not be or have been a PI on a substantial independent research award (R01, DP2, DP5, MIRA, or equivalent).</td>
<td>Decision on Letters of Intent: December 2022 For assistance with reviewing/editing your LOI, Washington University faculty may reach out to Glenn Floyd in Medical Corporate and Foundation Relations at <a href="mailto:floydg@wustl.edu">floydg@wustl.edu</a>.</td>
</tr>
<tr>
<td>October 19, 2021</td>
<td>American Cancer Society Clinical Trial Not Allowed</td>
<td>Pancreatic Cancer Action Network</td>
<td>$150,000 over 2 years</td>
<td>The Pancreatic Cancer Action Network Career Development Award represents an effort to encourage and support junior faculty to conduct pancreatic cancer research and establish successful career paths in the field. The grants provide $150,000 over two years for junior investigators that have yet to secure their first major research funding. The research proposed for funding may be basic, translational, clinical or epidemiological in nature and must have direct applicability and relevance to pancreatic cancer. Special consideration will be given to undertakings in pancreatic cancer research, minority researchers, and research focused on cancer health disparities.</td>
<td>At the start of the grant term on July 1, 2022, applicant must hold a faculty position with the title of Assistant Professor, Instructor, Research Assistant Professor or the equivalent and have completed their most recent doctoral degree within the past 11 years.</td>
<td>Earliest Start Date: July 2022</td>
</tr>
<tr>
<td>October 29, 2021</td>
<td>Pancreatic Cancer Action Network</td>
<td>Gateway for Cancer Research</td>
<td>$5.5M over 5 years</td>
<td>Gateway focuses on translational science via effective clinical trials—when basic science translates into human testing and clinical practice. We invited in Phase 1 and 2 clinical trials to enroll patients at all ages, with all cancer types, whose cancer is at any stage of progress—as long as they have the potential to help people live longer and feel better. Researchers should be prepared to demonstrate how the proposed study fits with GFCR’s mission and focuses on one or more of the following therapeutic areas: • New Investigational Therapies • Novel Use of Approach • Precision Medicine • Targeted Therapies</td>
<td>Applicants who are invited to submit a full application will be given 4-6 weeks to complete the grant. Gateway will place increasing emphasis on the funding patient-centered and novel research that includes approaches with a high potential for success. For more information on GFCR’s mission and areas of focus, visit: <a href="https://gatewayforcancer.org">https://gatewayforcancer.org</a></td>
<td>Grant recipients are expected to attend the PanCan Annual Scientific Summit. The meeting location and dates are TBD.</td>
</tr>
</tbody>
</table>
**LETTER OF INTENT:**

November 2, 2021 - 11:59PM CST

**NEW: GFCR Integrative Oncology Research Program Grant**

Gateway for Cancer Research

$1.5M over 5 years

Gateway is focused on funding integrative oncology research that pairs conventional therapies with evidence-based integrative therapies to manage symptoms and side effects from treatment. This also aims to increase quality of life, especially post-treatment.

Researchers should be prepared to demonstrate how the proposed study fits with GFCR’s mission and focuses on one or more of the following therapeutic areas:

- New Investigational Therapies
- Novel Use of Approach
- Precision Medicine
- Targeted Therapies

Applicants who are invited to submit a full application will be given 4-5 weeks to complete the grant.

**Companion Opportunity:** SIO Integrative Oncology Research Program Grant

---

**Sponsor**

<table>
<thead>
<tr>
<th>Sponsor</th>
<th>QUICK LINKS</th>
</tr>
</thead>
<tbody>
<tr>
<td>DOD</td>
<td><a href="https://cdmrp.army.mil/funding/default">https://cdmrp.army.mil/funding/default</a></td>
</tr>
<tr>
<td>NIH</td>
<td><a href="https://grants.nih.gov/funding/index.htm">https://grants.nih.gov/funding/index.htm</a></td>
</tr>
</tbody>
</table>

This newsletter is not fully inclusive of all available cancer-related funding. Please be sure to consult other sources to learn of other opportunities not listed above.